In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion The Pharmacology of Longevity: Peptide Edition (Part 1) FDA mulls compounding for peptides previously flagged over safety risks BioSpace
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols